How India Exports Gentamicin to the World

In the United States, gentamicin is approved for various indications, including the treatment of serious bacterial infections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for gentamicin, indicating a well-established generic market. Notably, on January 31, 1991, the FDA designated gentamicin-impregnated PMMA beads on surgical wire as an orphan drug for the treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin. However, this specific formulation has not received FDA approval for the orphan indication.

The substantial number of Indian exporters (509) underscores the competitive landscape for gentamicin in the U.S. market. To ensure compliance, exporters must adhere to the FDA's stringent regulatory requirements, including Good Manufacturing Practices (GMP) and accurate labeling standards. Additionally, vigilance regarding FDA import alerts is crucial, as any non-compliance can lead to shipment detentions or refusals.

In the European Union, gentamicin is subject to the European Medicines Agency's (EMA) regulatory oversight. The EMA has conducted periodic safety update report single assessments (PSUSAs) for gentamicin, with notable assessments in January 2018 and February 2024, leading to variations in product information to enhance safety and efficacy. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a Drug Safety Update in November 2017 concerning potential histamine-related adverse drug reactions associated with certain batches of gentamicin. This alert emphasized the importance of monitoring and reporting adverse reactions to ensure patient safety. (gov.uk)

Compliance with EU and UK GMP requirements is mandatory for exporters aiming to access these markets. This includes adherence to stringent quality control measures and regular inspections to maintain product integrity and safety.

Gentamicin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in treating severe bacterial infections. This inclusion highlights the antibiotic's importance in global health and its widespread use in various healthcare settings.

Regarding pharmacopoeial standards, gentamicin is listed in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards ensure the quality, purity, and potency of gentamicin formulations, providing a benchmark for manufacturers and regulatory authorities worldwide.

In India, gentamicin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. This classification mandates that gentamicin can only be sold or dispensed with a valid prescription from a registered medical practitioner.

The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines in India. As of March 2026, gentamicin is subject to price control measures to ensure affordability and accessibility. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of gentamicin formulations, ensuring compliance with national regulations and monitoring of pharmaceutical exports.

Gentamicin is an established antibiotic with no active patents or exclusivity rights, allowing for robust generic competition. This lack of patent protection has facilitated the entry of multiple manufacturers into the market, contributing to the significant number of Indian exporters (509) and the competitive pricing observed in international markets.

In April 2024, the EMA's Committee for Medicinal Products for Veterinary Use (CVMP) initiated a procedure to assess the need for including a maximum limit for histamine in gentamicin-containing medicinal products for parenteral administration to horses. This action was in response to adverse reactions linked to histamine residues in the active substance. (ema.europa.eu)

In February 2024, the EMA published the results of a periodic safety update report single assessment (PSUSA) for systemic gentamicin use, leading to variations in product information to enhance safety and efficacy. (ema.europa.eu)

In November 2025, the EMA updated the procedural steps and scientific information for Metalyse, a medicinal product containing tenecteplase, reflecting ongoing regulatory oversight and commitment to patient safety. (ema.europa.eu)

In October 2022, the EMA's CVMP adopted a positive opinion for Mometamax Ultra, a veterinary medicinal product containing gentamicin, mometasone furoate, and posaconazole, indicating continued regulatory approvals for gentamicin-containing products. (ema.europa.eu)

In September 2025, the EMA's CVMP highlighted the importance of pharmacovigilance and ongoing assessment of veterinary medicinal products, including those containing gentamicin, to ensure their continued safety and efficacy. (ema.europa.eu)

These developments underscore the dynamic regulatory environment surrounding gentamicin, emphasizing the need for exporters to stay informed and compliant with evolving standards and requirements.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API and KSM requirements are sourced from China. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact India's pharmaceutical production capabilities.

The COVID-19 pandemic highlighted the vulnerabilities of this reliance. When Chinese factories shut down, the supply of common APIs dried up almost instantly, leading to price surges for everyday drugs. To mitigate such risks, India has initiated the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of critical pharmaceutical ingredients and reduce import dependence. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, which are crucial for several common antibiotics.

Our proprietary trade data indicates that the top five exporters of Gentamicin from India account for 48.5% of the total export value, with LINCOLN PHARMACEUTICALS LTD leading at a 14.0% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact the global supply of Gentamicin.

The PLI scheme, launched in 2020, aims to reduce India's dependency on imports by incentivizing domestic production of critical APIs and KSMs. While progress has been made, with new plants inaugurated in 2024, the full impact on reducing supplier concentration and mitigating single-source risks is yet to be realized.

Recent geopolitical tensions have further strained global supply chains. In February 2026, the closure of the Strait of Hormuz following attacks on Iran by the US and Israel disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Additionally, threats to commercial shipping in the Red Sea and Gulf of Aden have escalated, with warnings of potential attacks on vessels transiting these regions.

While there have been no specific FDA or EMA shortage alerts for Gentamicin as of March 2026, the combination of raw material dependencies and shipping disruptions underscores the need for proactive risk management strategies.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Accelerate initiatives like the PLI scheme to bolster local manufacturing capabilities for critical pharmaceutical ingredients.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact supply chains and develop contingency plans accordingly.

• Strengthen Inventory Management: Maintain strategic stockpiles of essential APIs and KSMs to buffer against potential supply disruptions.

• Collaborate with Regulatory Bodies: Work closely with organizations like the FDA and EMA to stay informed about potential shortages and regulatory changes.

RISK_LEVEL: MEDIUM